Actavis To Leave China, Saying Risks Outweigh Potential Gains
This article was originally published in PharmAsia News
Executive Summary
Actavis, a global leader in generic drugs, plans to pull out of China altogether, saying its 1.3 billion potential customers are not enough to justify the difficulties of operating in a country it considers unfriendly to business.